Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...
Yahoo Finance12d
Neurocrine Biosciences' (NASDAQ:NBIX) underlying earnings growth outpaced the notable return generated for shareholders over the past three years
It's been a soft week for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares, which are down 19%. But we wouldn't complain about the gain over the last three years. In that time the stock gained 43 ...
Yahoo Finance28d
Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device
Dr. Ratz joins Neurocrine after a 28-year career at Eli ... of more than 25 products across multiple therapeutic areas and molecule modalities. Most recently, he served as Lilly's Senior Vice ...
AOL13d
Why Is Neurocrine Biosciences Stock Trading Lower On Friday?
On Thursday, Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56. The company ...